$SNGX News
Last published 5d ago
- 5d agoSNGXSoligenix Announces Recent Updates and Third Quarter 2026 Financial ResultsPR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing products to...
- 3mo agoSNGXSoligenix Announces Recent Updates and Second Quarter 2026 Financial ResultsPR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing products to treat...
- 5mo agoSNGXSoligenix Applying for Vaccine Development Funding for Bundibugyo Ebola VaccinePR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 5mo agoSNGXSuitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in CongoPR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 6mo agoSNGXSoligenix Announces Recent Updates and First Quarter 2026 Financial ResultsPR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 6mo agoSNGXSoligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell LymphomaPR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 7mo agoSNGXPositive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and TherapyPR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 7mo agoSNGXSoligenix Announces Recent Accomplishments and Year End 2025 Financial ResultsPR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 7mo agoSNGXSoligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's DiseasePR Newswireoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 7mo agoSNGXHyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026PR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 7mo agoSNGXSoligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"PR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 8mo agoSNGXSoligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory AgencyPR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 8mo agoSNGXSoligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's DiseasePR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 8mo agoSNGXSoligenix to Present at BIO Investment & Growth SummitPR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 9mo agoSNGXSoligenix Details Recent Progress and Upcoming MilestonesPR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 10mo agoSNGXPositive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)PR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 10mo agoSNGXSoligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate PsoriasisPR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 11mo agoSNGXNetworkNewsAudio Announces Audio Press Release (APR) on Final Confirmatory Clinical Study Being Done for Treatment of Rare DiseaseGlobeNewswireAUSTIN, Texas, Dec. 10, 2025 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled ""Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now,"
- 11mo agoSNGXSoligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal CrossroadGlobeNewswireNEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- via BioMedWire: — Soligenix Inc. (NASDAQ:SNGX) today announces its placement in an editorial published by BioMedWire ("BMW"), one of 75+ brands within the Dynamic
- 11mo agoAMGNCTORFOLDSNGX+1Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging PopulationsGlobeNewswireAUSTIN, Texas, Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Chronic illnesses and rare disorders among older Americans represent a rapidly intensifying challenge for the U.S. healthcare system, with
- 11mo agoSNGXSoligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL SpaceGlobeNewswireNEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- via BioMedWire: — Soligenix Inc. (NASDAQ:SNGX) today announces its placement in an editorial published by BioMedWire ("BMW"), one of 75+ brands within the Dynamic
- 11mo agoBMYINSMMRKPFE+1Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter NowGlobeNewswireAUSTIN, Texas, Dec. 02, 2025 (GLOBE NEWSWIRE) -- BioMedWire: Chronic conditions and rare diseases in the aging population present an urgent and expanding challenge within the U.S. healthcare system, especially as more
- 11mo agoSNGXSoligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell LymphomaPR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 1y agoSNGXSoligenix Announces Recent Accomplishments and Third Quarter 2025 Financial ResultsPR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 1y agoSNGXSoligenix Updates United States Medical Advisory Board for Cutaneous T-Cell LymphomaPR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 1y agoSNGXSoligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell LymphomaPR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 1y agoSNGXSoligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell LymphomaPR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 1y agoSNGXSoligenix Announces Closing of $7.5 Million Public OfferingPR NewswireSoligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializing...
- 1y agoSNGXSoligenix Announces Pricing of $7.5 Million Public OfferingPR NewswireSoligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializing...
- 1y agoSNGXSoligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic AdvisorPR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 1y agoSNGXSoligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related VirusesPR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 1y agoSNGXSoligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment ConferencePR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 1y agoSNGXFDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study ResultsPR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 1y agoSNGXSoligenix Announces Recent Accomplishments And Second Quarter 2025 Financial ResultsPR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 1y agoSNGXNetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin CancerGlobeNewswireAUSTIN, Texas, Aug. 08, 2025 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled "Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas,"
- 1y agoSNGXSoligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL TherapyGlobeNewswireNEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Soligenix Inc. (NASDAQ:SNGX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands
- 1y agoSNGXAMGNFOLDTNXP+1Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for InnovatorsPR NewswireAs the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, particularly for older adults. The...
- 1y agoSNGXSoligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL SpaceGlobeNewswireNEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Soligenix Inc. (NASDAQ:SNGX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands
- 1y agoSNGXPFEMRKBMY+1Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic AreasPR NewswireAs America's population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that disproportionately affects older...
- 1y agoSNGXBiological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's DiseasePR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 1y agoSNGXSoligenix Corporate Update Letter - Key Highlights and Upcoming MilestonesPR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 1y agoSNGXSoligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma SolutionsPR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 1y agoSNGXSoligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical TrialsGlobeNewswirePRINCETON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat
- 1y agoSNGXSoligenix Announces Recent Accomplishments And First Quarter 2025 Financial ResultsPR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 1y agoSNGXIBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Christopher Schaber, CEO of Soligenix Inc.GlobeNewswireAUSTIN, Texas, May 07, 2025 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the
- 1y agoSNGXPositive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 WeeksPR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 1y agoSNGXIBN Initiates Coverage of Soligenix Inc.GlobeNewswireAUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix Inc. (NASDAQ:SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases with an unmet
- 1y agoSNGXSoligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 VariantsPR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 1y agoSNGXSoligenix Announces Recent Accomplishments and Year End 2024 Financial ResultsPR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
- 1y agoSNGXHyBryte™ Treatment Studies Presented at Two Medical Conferences in MarchPR NewswireSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...